Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received an average rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $13.75.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of TBPH. Invesco Ltd. lifted its position in shares of Theravance Biopharma by 3.5% during the 4th quarter. Invesco Ltd. now owns 46,050 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 1,576 shares during the period. Jane Street Group LLC boosted its holdings in Theravance Biopharma by 1.1% in the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 1,640 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Theravance Biopharma by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company’s stock valued at $2,766,000 after acquiring an additional 2,060 shares during the period. Aquatic Capital Management LLC bought a new stake in shares of Theravance Biopharma during the fourth quarter valued at approximately $25,000. Finally, SG Americas Securities LLC raised its position in shares of Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,349 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Stock Down 4.8 %

NASDAQ TBPH opened at $8.86 on Tuesday. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.90. The business’s fifty day moving average is $9.38 and its 200 day moving average is $8.90. The company has a market cap of $435.68 million, a price-to-earnings ratio of -8.77 and a beta of 0.21.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.